NEW PRESS RELEASE >> Sylentis announces new preclinical and clinical data for its SYL1001 molecule during ARVO 2017
Groundbreaking research in Dry Eye Disease will be presented at the Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO) in Baltimore, Maryland from May 7-11, 2017.
Three Sylentis’ abstracts were selected for poster presentations.
The scheduled times (noted in local Eastern Time) and presentation titles are as follows:
|
May 7, 2017 1:30 - 3:15 PM
- Efficacy of SYL1001 in different animal models of Dry Eye Disease A.I. Jiménez PhD., C. Paneda PhD., T. Martínez PhD., A. Guerra, N. Fonseca, S. Monteiro, C. Salvador, J. Merayo-Lloves PhD., I. Alcalde PhD., V. Ruz PhD., V. González PhD.
Posterboard Number: 458 - A0383
Session Number: 133
Session Title: Dry eye, non-clinical
Session Date/ Times: May 7, 2017 1:30 pm - 3:15 pm
- Stability study of SYL1001 eye drops (a siRNA compound) for DED in different containers. L. Company PhD.; V. González PhD.; Y. Ruiz.; C. Astrain.; C. Segura.; N. Miguel.; C. Millán.; A.I. Jiménez PhD
Posterboard Number: 476 – A0401
Session Number: 133 Session
Session Title: Dry eye, non-clinical
Session Date/ Times: May 7, 2017 1:30 pm - 3:15 pm
|
| |
|
May 9, 2017 8:30 - 10:15 AM
- Clinical and preclinical study correlation for SYL1001, a new treatment for dry eye disease. V. González PhD., V. Ruz PhD., C. Paneda PhD., A.M. Bleau PhD., B. Vargas MSc, A.I. Jiménez PhD.
Posterboard Number: 2670 - A0260
Session Number: 315
Session Title: Dry eye, clinical
Session Date/ Times: May 9, 2017 8:30 am - 10:15
|
